Get the Stockscreener App
11.32
8.27%
-1.02
Sellas Life Sciences Group Inc stock is traded at $11.32, with a volume of 6.70M.
It is down -8.27% in the last 24 hours and up +23.45% over the past month.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
See More
Previous Close:
$12.34
Open:
$12.34
24h Volume:
6.70M
Relative Volume:
0.74
Market Cap:
$2.23B
Revenue:
-
Net Income/Loss:
$-29.46M
P/E Ratio:
-49.58
EPS:
-0.2283
Net Cash Flow:
$-28.17M
1W Performance:
-14.18%
1M Performance:
+23.45%
6M Performance:
+165.73%
1Y Performance:
+518.58%
1-Day Range:
$11.22
$12.48
1-Week Range:
$11.22
$13.58
52-Week Range:
$1.39
$15.88
Sellas Life Sciences Group Inc Stock (SLS) Company Profile
Name
Sellas Life Sciences Group Inc
Sector
Industry
Phone
(646) 200-5278
Address
7 TIMES SQUARE, NEW YORK, NY
Compare SLS vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLS
Sellas Life Sciences Group Inc
|
11.32 | 2.23B | 0 | -29.46M | -28.17M | -0.2283 |
VRTX
Vertex Pharmaceuticals Inc
|
477.36 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
656.01 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
918.22 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.23 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.77 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Sellas Life Sciences Group Inc Stock (SLS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-21-21 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-01-18 | Initiated | Oppenheimer | Outperform |
| Apr-02-18 | Initiated | H.C. Wainwright | Buy |
| Mar-19-18 | Upgrade | Maxim Group | Hold → Buy |
Sellas Life Sciences Group Inc Stock (SLS) Latest News
SELLAS Life Sciences Group, Inc. Revenue Breakdown – LS:A2PU3T - TradingView
SLS Stock Rises Overnight: Traders Rally Behind Jim Cramer's 'Two Thumbs Up' Call Ahead Of Key AML Readout - Stocktwits
SLS Stock Rises Overnight: Retail Traders Call New AML Survival Data 'Huge' Ahead Of CEO’s Fox Appearance - Stocktwits
SLS Stock Hits Over 3-Year High As AML Drug Trial Nears Final Readout — Wall Street Sees 30% More Upside - Stocktwits
SLS Stock Gains Momentum: NVDA, MSFT Investor Loads Up Ahead Of AML Trial Milestone Trigger - Stocktwits
SLS: SELLAS Life Sciences Group Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Sellas CEO Angelos Stergiou Says ‘100% Certain’ AI Can Be Used To Beat Cancer - Stocktwits
SLS Stock Hits 4-Year High: BlackRock Stake Boost Fuels Buzz Around Looming AML Trial Readout - Stocktwits
SLS Stock Jumps Premarket: CEO Says GPS AML Data Has ‘Very Good Chance’ To Beat Earlier Survival Outcomes - Stocktwits
SLS Stock Extends Rally Overnight: CEO Says ‘Bullish’ Leukemia Data Could Drive NCCN Recognition For GPS - Stocktwits
Is SELLAS Life Sciences Group (SLS) Fully Priced As Regal Trial Debate Heats Up? - simplywall.st
Greenwich LifeSciences, Inc. (GLSI) Stock Price, News, Quote & History - Yahoo! Finance Canada
Greenwich LifeSciences, Inc. (GLSI) stock price, news, quote and history - Yahoo Finance UK
SLS Stock July Rout Deepens: ‘Pharma Bro’ Martin Shkreli Questions Timing Of AML Trial, Says Data May Wait Until Christmas - Stocktwits
SLS Stock Surges Toward Fifth Weekly Rise: CEO Touts GPS As Lifeline For Elderly Patients As Cancer Summit Looms - Stocktwits
SLS Stock Whipsaws As Meme Momentum Meets Biotech Reality - StocksToTrade
SELLAS Life Sciences Group Inc (SLS) Earnings, Actual EPS, EPS Estimates & Results - Stocktwits
SLS Stock Surges Into Conference Season As Investors Hunt For AML Readout Hints - Stocktwits
SLS Stock Sparks Retail Buzz Ahead of AACR Presentation On Experimental Cancer Therapy - Stocktwits
Why Did SLS, BB, OUST Stocks Surge To 52-Week Highs Today? - Stocktwits
SLS Stock Kicks Off Week In Green: CEO Flags Role In EU Biotech Policy Talks That Could Impact Drug Approvals - Stocktwits
SELLAS Life Sciences Group Stock Short Interest Falls to 32.33% - Quiver Quantitative
SLS Stock Rises Overnight: Retail Thinks CEO Just Dropped Buyout Clues Ahead Of Fox Appearance - Stocktwits
NBIS, CSCO, SLS Stocks Hit 52-Week Highs Today: What's Behind The Surge? - Stocktwits
SLS Stock Jumps Ahead Of CEO’s Fox Appearance: Retail Bets AML Readout Could Spark Big Pharma Bidding War - Yahoo Finance
SLS Stock Jumps Overnight: ‘Potent’ AML Drug Data Ahead Of Cancer Summit Fuels Fresh Momentum - Stocktwits
Will Near-Complete REGAL Phase 3 GPS Data and New Executive Terms Change SELLAS Life Sciences Group's (SLS) Narrative - Yahoo Finance
SLS Stock Hits Over 4-Year High: CEO Eyes FDA Talks, ‘Whole Gamut’ Of Cancer Uses For GPS - Stocktwits
SLS Stock Tests $5 Again: Retail Targets ‘No’ Vote On 20M Share Dilution Push Before AML Trial Results - Stocktwits
SELLAS Life Sciences Group (NASDAQ:SLS) surge draws attention to $319 million market-cap deficit ahead of REGAL trial results - TechStock²
SLS Stock Pops Big After Hours On Imminent Leukemia Trial Data Readout Optimism - Stocktwits
Sellas Life Sciences Draws Significant Retail Buzz As Traders Eye REGAL Phase 3 Catalyst – SLS Stock Soars 15% - Stocktwits
SELLAS Life Sciences Group (SLS) Stock Looks Rich On Book Value Yet Strong On Returns - Yahoo Finance
SELLAS Life Sciences Group (SLS) Stock Pricey Following Phase 3 Trial Buzz - Yahoo Finance
SLS News | SELLAS LIFE SCIENCES GROUP I (NASDAQ:SLS) - ChartMill
SLS Stock Tanks Hard: Retail Traders Blame Warrant Holders, 'Flippers' Cashing Out Before AML Catalyst - Stocktwits
SELLAS Life Sciences (NASDAQ:SLS) Shares Climb 12% as Estimated Equity Value Rises $1.6 Billion Since May - TechStock²
SELLAS Life Sciences rebounds 12% as investors continue to wait for key data (SLS:NASDAQ) - Seeking Alpha
Sellas Life Sciences Group Inc Stock (SLS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.46%
0.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):